instruction stringlengths 34 186 | input stringlengths 2.02k 93.8k | output stringlengths 2 418 | meta_questiontype stringclasses 6
values | meta_inputlicense stringclasses 6
values | meta_pmid stringlengths 8 8 | meta_safetyreportid int64 9.51M 21M | meta_articlepubdate stringlengths 4 10 |
|---|---|---|---|---|---|---|---|
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Squamous cell carcinoma of the cervix'. | Modified combined radiotherapy for cervical cancer in kidney transplant recipient.
The management of locally advanced cervical cancer in patients with a pelvic kidney transplant is challenging because standard chemoradiotherapy may increase the risk of ureteral stenosis and obstruction or vascular damage of the graft. ... | CYCLOSPORINE, EVEROLIMUS, METHYLPREDNISOLONE | DrugsGivenReaction | CC BY-NC-ND | 33936645 | 19,776,188 | 2021-04 |
What was the outcome of reaction 'Cervix carcinoma stage II'? | Modified combined radiotherapy for cervical cancer in kidney transplant recipient.
The management of locally advanced cervical cancer in patients with a pelvic kidney transplant is challenging because standard chemoradiotherapy may increase the risk of ureteral stenosis and obstruction or vascular damage of the graft. ... | Recovering | ReactionOutcome | CC BY-NC-ND | 33936645 | 19,715,593 | 2021-04 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Anaemia'. | Thrombocytosis in a patient with acute promyelocytic leukemia during treatment with all-trans retinoic acid and arsenic trioxide.
Thrombocytosis is an unusual side effect of all-trans retinoic acid (ATRA) treatment that occurs in some patients with acute promyelocytic leukemia (APL).
1 INTRODUCTION
Thrombocytosis, an ... | ARSENIC, TRETINOIN | DrugsGivenReaction | CC BY | 33936662 | 19,280,119 | 2021-04 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Cerebral haemorrhage'. | Thrombocytosis in a patient with acute promyelocytic leukemia during treatment with all-trans retinoic acid and arsenic trioxide.
Thrombocytosis is an unusual side effect of all-trans retinoic acid (ATRA) treatment that occurs in some patients with acute promyelocytic leukemia (APL).
1 INTRODUCTION
Thrombocytosis, an ... | ARSENIC TRIOXIDE, TRETINOIN | DrugsGivenReaction | CC BY | 33936662 | 19,267,880 | 2021-04 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Depressed level of consciousness'. | Thrombocytosis in a patient with acute promyelocytic leukemia during treatment with all-trans retinoic acid and arsenic trioxide.
Thrombocytosis is an unusual side effect of all-trans retinoic acid (ATRA) treatment that occurs in some patients with acute promyelocytic leukemia (APL).
1 INTRODUCTION
Thrombocytosis, an ... | ARSENIC, TRETINOIN | DrugsGivenReaction | CC BY | 33936662 | 19,280,119 | 2021-04 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Headache'. | Thrombocytosis in a patient with acute promyelocytic leukemia during treatment with all-trans retinoic acid and arsenic trioxide.
Thrombocytosis is an unusual side effect of all-trans retinoic acid (ATRA) treatment that occurs in some patients with acute promyelocytic leukemia (APL).
1 INTRODUCTION
Thrombocytosis, an ... | ARSENIC, TRETINOIN | DrugsGivenReaction | CC BY | 33936662 | 19,280,119 | 2021-04 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Retinal haemorrhage'. | Thrombocytosis in a patient with acute promyelocytic leukemia during treatment with all-trans retinoic acid and arsenic trioxide.
Thrombocytosis is an unusual side effect of all-trans retinoic acid (ATRA) treatment that occurs in some patients with acute promyelocytic leukemia (APL).
1 INTRODUCTION
Thrombocytosis, an ... | ARSENIC, TRETINOIN | DrugsGivenReaction | CC BY | 33936662 | 19,280,119 | 2021-04 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Seizure'. | Thrombocytosis in a patient with acute promyelocytic leukemia during treatment with all-trans retinoic acid and arsenic trioxide.
Thrombocytosis is an unusual side effect of all-trans retinoic acid (ATRA) treatment that occurs in some patients with acute promyelocytic leukemia (APL).
1 INTRODUCTION
Thrombocytosis, an ... | ARSENIC, TRETINOIN | DrugsGivenReaction | CC BY | 33936662 | 19,280,119 | 2021-04 |
What was the administration route of drug 'ARSENIC TRIOXIDE'? | Thrombocytosis in a patient with acute promyelocytic leukemia during treatment with all-trans retinoic acid and arsenic trioxide.
Thrombocytosis is an unusual side effect of all-trans retinoic acid (ATRA) treatment that occurs in some patients with acute promyelocytic leukemia (APL).
1 INTRODUCTION
Thrombocytosis, an ... | Intravenous (not otherwise specified) | DrugAdministrationRoute | CC BY | 33936662 | 19,267,880 | 2021-04 |
What was the administration route of drug 'ARSENIC'? | Thrombocytosis in a patient with acute promyelocytic leukemia during treatment with all-trans retinoic acid and arsenic trioxide.
Thrombocytosis is an unusual side effect of all-trans retinoic acid (ATRA) treatment that occurs in some patients with acute promyelocytic leukemia (APL).
1 INTRODUCTION
Thrombocytosis, an ... | Intravenous (not otherwise specified) | DrugAdministrationRoute | CC BY | 33936662 | 19,280,119 | 2021-04 |
What was the administration route of drug 'TRETINOIN'? | Thrombocytosis in a patient with acute promyelocytic leukemia during treatment with all-trans retinoic acid and arsenic trioxide.
Thrombocytosis is an unusual side effect of all-trans retinoic acid (ATRA) treatment that occurs in some patients with acute promyelocytic leukemia (APL).
1 INTRODUCTION
Thrombocytosis, an ... | Oral | DrugAdministrationRoute | CC BY | 33936662 | 19,280,119 | 2021-04 |
What was the dosage of drug 'ARSENIC TRIOXIDE'? | Thrombocytosis in a patient with acute promyelocytic leukemia during treatment with all-trans retinoic acid and arsenic trioxide.
Thrombocytosis is an unusual side effect of all-trans retinoic acid (ATRA) treatment that occurs in some patients with acute promyelocytic leukemia (APL).
1 INTRODUCTION
Thrombocytosis, an ... | 0.15 MG/KG, 1X/DAY | DrugDosageText | CC BY | 33936662 | 19,141,891 | 2021-04 |
What was the dosage of drug 'TRETINOIN'? | Thrombocytosis in a patient with acute promyelocytic leukemia during treatment with all-trans retinoic acid and arsenic trioxide.
Thrombocytosis is an unusual side effect of all-trans retinoic acid (ATRA) treatment that occurs in some patients with acute promyelocytic leukemia (APL).
1 INTRODUCTION
Thrombocytosis, an ... | 45 MG/M2, 1X/DAY | DrugDosageText | CC BY | 33936662 | 19,141,891 | 2021-04 |
What was the outcome of reaction 'Cerebral haemorrhage'? | Thrombocytosis in a patient with acute promyelocytic leukemia during treatment with all-trans retinoic acid and arsenic trioxide.
Thrombocytosis is an unusual side effect of all-trans retinoic acid (ATRA) treatment that occurs in some patients with acute promyelocytic leukemia (APL).
1 INTRODUCTION
Thrombocytosis, an ... | Recovered | ReactionOutcome | CC BY | 33936662 | 19,267,880 | 2021-04 |
What was the outcome of reaction 'Seizure'? | Thrombocytosis in a patient with acute promyelocytic leukemia during treatment with all-trans retinoic acid and arsenic trioxide.
Thrombocytosis is an unusual side effect of all-trans retinoic acid (ATRA) treatment that occurs in some patients with acute promyelocytic leukemia (APL).
1 INTRODUCTION
Thrombocytosis, an ... | Recovered | ReactionOutcome | CC BY | 33936662 | 19,280,119 | 2021-04 |
What was the outcome of reaction 'Thrombocytosis'? | Thrombocytosis in a patient with acute promyelocytic leukemia during treatment with all-trans retinoic acid and arsenic trioxide.
Thrombocytosis is an unusual side effect of all-trans retinoic acid (ATRA) treatment that occurs in some patients with acute promyelocytic leukemia (APL).
1 INTRODUCTION
Thrombocytosis, an ... | Recovered | ReactionOutcome | CC BY | 33936662 | 19,280,119 | 2021-04 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Off label use'. | Salmonella osteomyelitis complicating aseptic osteonecrosis: Don't forget about the antiphospholipid syndrome.
Osteonecrosis in antiphospholipid syndrome is a diagnostic challenge for clinicians. Early diagnosis and intervention are important for better prognosis.
1 INTRODUCTION
The antiphospholipid syndrome is charac... | MYCOPHENOLATE MOFETIL, MYCOPHENOLIC ACID, PREDNISONE | DrugsGivenReaction | CC BY-NC-ND | 33936665 | 19,314,055 | 2021-04 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Osteomyelitis salmonella'. | Salmonella osteomyelitis complicating aseptic osteonecrosis: Don't forget about the antiphospholipid syndrome.
Osteonecrosis in antiphospholipid syndrome is a diagnostic challenge for clinicians. Early diagnosis and intervention are important for better prognosis.
1 INTRODUCTION
The antiphospholipid syndrome is charac... | MYCOPHENOLATE MOFETIL, MYCOPHENOLIC ACID, PREDNISONE | DrugsGivenReaction | CC BY-NC-ND | 33936665 | 19,314,055 | 2021-04 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Osteonecrosis'. | Salmonella osteomyelitis complicating aseptic osteonecrosis: Don't forget about the antiphospholipid syndrome.
Osteonecrosis in antiphospholipid syndrome is a diagnostic challenge for clinicians. Early diagnosis and intervention are important for better prognosis.
1 INTRODUCTION
The antiphospholipid syndrome is charac... | MYCOPHENOLATE MOFETIL, MYCOPHENOLIC ACID, PREDNISONE | DrugsGivenReaction | CC BY-NC-ND | 33936665 | 19,314,055 | 2021-04 |
What was the dosage of drug 'MYCOPHENOLIC ACID'? | Salmonella osteomyelitis complicating aseptic osteonecrosis: Don't forget about the antiphospholipid syndrome.
Osteonecrosis in antiphospholipid syndrome is a diagnostic challenge for clinicians. Early diagnosis and intervention are important for better prognosis.
1 INTRODUCTION
The antiphospholipid syndrome is charac... | 3 G | DrugDosageText | CC BY-NC-ND | 33936665 | 19,314,055 | 2021-04 |
What was the dosage of drug 'PREDNISONE'? | Salmonella osteomyelitis complicating aseptic osteonecrosis: Don't forget about the antiphospholipid syndrome.
Osteonecrosis in antiphospholipid syndrome is a diagnostic challenge for clinicians. Early diagnosis and intervention are important for better prognosis.
1 INTRODUCTION
The antiphospholipid syndrome is charac... | 1 MG/KG | DrugDosageText | CC BY-NC-ND | 33936665 | 19,314,055 | 2021-04 |
What was the outcome of reaction 'Osteomyelitis salmonella'? | Salmonella osteomyelitis complicating aseptic osteonecrosis: Don't forget about the antiphospholipid syndrome.
Osteonecrosis in antiphospholipid syndrome is a diagnostic challenge for clinicians. Early diagnosis and intervention are important for better prognosis.
1 INTRODUCTION
The antiphospholipid syndrome is charac... | Recovered | ReactionOutcome | CC BY-NC-ND | 33936665 | 19,314,055 | 2021-04 |
What was the outcome of reaction 'Osteonecrosis'? | Salmonella osteomyelitis complicating aseptic osteonecrosis: Don't forget about the antiphospholipid syndrome.
Osteonecrosis in antiphospholipid syndrome is a diagnostic challenge for clinicians. Early diagnosis and intervention are important for better prognosis.
1 INTRODUCTION
The antiphospholipid syndrome is charac... | Recovered | ReactionOutcome | CC BY-NC-ND | 33936665 | 19,314,055 | 2021-04 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Abdominal pain'. | Dexamethasone and diclofenac intramuscular mixture injection and risk of death: A case series study.
Diclofenac and dexamethasone injection mixture could be associated with fatal cardiovascular events, further studies are warrantied to explore the safety of this injection mixture and explore the genetic role of it.
1 C... | ACETAMINOPHEN, DEXAMETHASONE, DICLOFENAC SODIUM | DrugsGivenReaction | CC BY-NC | 33936668 | 19,056,895 | 2021-04 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Decreased appetite'. | Dexamethasone and diclofenac intramuscular mixture injection and risk of death: A case series study.
Diclofenac and dexamethasone injection mixture could be associated with fatal cardiovascular events, further studies are warrantied to explore the safety of this injection mixture and explore the genetic role of it.
1 C... | ACETAMINOPHEN, DEXAMETHASONE, DICLOFENAC SODIUM | DrugsGivenReaction | CC BY-NC | 33936668 | 19,056,895 | 2021-04 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Headache'. | Dexamethasone and diclofenac intramuscular mixture injection and risk of death: A case series study.
Diclofenac and dexamethasone injection mixture could be associated with fatal cardiovascular events, further studies are warrantied to explore the safety of this injection mixture and explore the genetic role of it.
1 C... | .ALPHA.-TOCOPHEROL, DEXAMETHASONE, DICLOFENAC SODIUM, ENALAPRIL, SPIRONOLACTONE, UNSPECIFIED INGREDIENT | DrugsGivenReaction | CC BY-NC | 33936668 | 19,056,896 | 2021-04 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Hyperthermia'. | Dexamethasone and diclofenac intramuscular mixture injection and risk of death: A case series study.
Diclofenac and dexamethasone injection mixture could be associated with fatal cardiovascular events, further studies are warrantied to explore the safety of this injection mixture and explore the genetic role of it.
1 C... | ACETAMINOPHEN, DEXAMETHASONE, DICLOFENAC SODIUM | DrugsGivenReaction | CC BY-NC | 33936668 | 19,056,895 | 2021-04 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Vomiting'. | Dexamethasone and diclofenac intramuscular mixture injection and risk of death: A case series study.
Diclofenac and dexamethasone injection mixture could be associated with fatal cardiovascular events, further studies are warrantied to explore the safety of this injection mixture and explore the genetic role of it.
1 C... | ACETAMINOPHEN, DEXAMETHASONE, DICLOFENAC SODIUM | DrugsGivenReaction | CC BY-NC | 33936668 | 19,056,895 | 2021-04 |
What was the administration route of drug 'DEXAMETHASONE'? | Dexamethasone and diclofenac intramuscular mixture injection and risk of death: A case series study.
Diclofenac and dexamethasone injection mixture could be associated with fatal cardiovascular events, further studies are warrantied to explore the safety of this injection mixture and explore the genetic role of it.
1 C... | Intramuscular | DrugAdministrationRoute | CC BY-NC | 33936668 | 19,069,856 | 2021-04 |
What was the administration route of drug 'DICLOFENAC SODIUM'? | Dexamethasone and diclofenac intramuscular mixture injection and risk of death: A case series study.
Diclofenac and dexamethasone injection mixture could be associated with fatal cardiovascular events, further studies are warrantied to explore the safety of this injection mixture and explore the genetic role of it.
1 C... | Intramuscular | DrugAdministrationRoute | CC BY-NC | 33936668 | 19,069,856 | 2021-04 |
What was the administration route of drug 'DICLOFENAC'? | Dexamethasone and diclofenac intramuscular mixture injection and risk of death: A case series study.
Diclofenac and dexamethasone injection mixture could be associated with fatal cardiovascular events, further studies are warrantied to explore the safety of this injection mixture and explore the genetic role of it.
1 C... | Intramuscular | DrugAdministrationRoute | CC BY-NC | 33936668 | 19,291,842 | 2021-04 |
What was the outcome of reaction 'Myocardial infarction'? | Dexamethasone and diclofenac intramuscular mixture injection and risk of death: A case series study.
Diclofenac and dexamethasone injection mixture could be associated with fatal cardiovascular events, further studies are warrantied to explore the safety of this injection mixture and explore the genetic role of it.
1 C... | Fatal | ReactionOutcome | CC BY-NC | 33936668 | 19,069,856 | 2021-04 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Drug ineffective'. | Richter's transformation as leptomeningeal infiltration in a chronic lymphocytic leukemia patient receiving venetoclax. Could blood-brain barrier be a disease "sanctuary" during venetoclax treatment?
Our unique case of Richter's Transformation presenting as leptomeningial infiltration in a CLL patient receiving venetoc... | DEXAMETHASONE, METHOTREXATE | DrugsGivenReaction | CC BY-NC-ND | 33936674 | 19,424,843 | 2021-04 |
What was the administration route of drug 'DEXAMETHASONE'? | Richter's transformation as leptomeningeal infiltration in a chronic lymphocytic leukemia patient receiving venetoclax. Could blood-brain barrier be a disease "sanctuary" during venetoclax treatment?
Our unique case of Richter's Transformation presenting as leptomeningial infiltration in a CLL patient receiving venetoc... | Intrathecal | DrugAdministrationRoute | CC BY-NC-ND | 33936674 | 19,424,843 | 2021-04 |
What was the dosage of drug 'METHOTREXATE'? | Richter's transformation as leptomeningeal infiltration in a chronic lymphocytic leukemia patient receiving venetoclax. Could blood-brain barrier be a disease "sanctuary" during venetoclax treatment?
Our unique case of Richter's Transformation presenting as leptomeningial infiltration in a CLL patient receiving venetoc... | 15 MG , UNK | DrugDosageText | CC BY-NC-ND | 33936674 | 19,424,843 | 2021-04 |
What was the outcome of reaction 'Drug ineffective'? | Richter's transformation as leptomeningeal infiltration in a chronic lymphocytic leukemia patient receiving venetoclax. Could blood-brain barrier be a disease "sanctuary" during venetoclax treatment?
Our unique case of Richter's Transformation presenting as leptomeningial infiltration in a CLL patient receiving venetoc... | Fatal | ReactionOutcome | CC BY-NC-ND | 33936674 | 19,424,843 | 2021-04 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Disease progression'. | Dual HER2 blockade with lapatinib and trastuzumab in combination with chemotherapy in metastatic gastroesophageal adenocarcinoma.
The development of resistance to trastuzumab in HER2-positive gastroesophageal cancer remains a problem. The use of dual HER2 blockade to overcome this is a therapeutic strategy that should ... | CAPECITABINE, LAPATINIB, TRASTUZUMAB | DrugsGivenReaction | CC BY-NC-ND | 33936677 | 19,356,254 | 2021-04 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Tumour marker increased'. | Dual HER2 blockade with lapatinib and trastuzumab in combination with chemotherapy in metastatic gastroesophageal adenocarcinoma.
The development of resistance to trastuzumab in HER2-positive gastroesophageal cancer remains a problem. The use of dual HER2 blockade to overcome this is a therapeutic strategy that should ... | CAPECITABINE, LAPATINIB, TRASTUZUMAB | DrugsGivenReaction | CC BY-NC-ND | 33936677 | 19,356,254 | 2021-04 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Goitre'. | Prenatal management of fetal goiter alternating between hypothyroidism and hyperthyroidism in a mother with Graves' disease.
We present a rare documented case with consecutive hypo- and hyperthyroidism during fetal life. First, hypothyroidism was due to transplacental passage of antithyroid drugs. After the mother's th... | PROPYLTHIOURACIL | DrugsGivenReaction | CC BY-NC-ND | 33936679 | 19,374,778 | 2021-04 |
What was the administration route of drug 'PROPYLTHIOURACIL'? | Prenatal management of fetal goiter alternating between hypothyroidism and hyperthyroidism in a mother with Graves' disease.
We present a rare documented case with consecutive hypo- and hyperthyroidism during fetal life. First, hypothyroidism was due to transplacental passage of antithyroid drugs. After the mother's th... | Transplacental | DrugAdministrationRoute | CC BY-NC-ND | 33936679 | 19,374,778 | 2021-04 |
What was the outcome of reaction 'Goitre'? | Prenatal management of fetal goiter alternating between hypothyroidism and hyperthyroidism in a mother with Graves' disease.
We present a rare documented case with consecutive hypo- and hyperthyroidism during fetal life. First, hypothyroidism was due to transplacental passage of antithyroid drugs. After the mother's th... | Recovered | ReactionOutcome | CC BY-NC-ND | 33936679 | 19,374,778 | 2021-04 |
What was the outcome of reaction 'Hyperthyroidism'? | Prenatal management of fetal goiter alternating between hypothyroidism and hyperthyroidism in a mother with Graves' disease.
We present a rare documented case with consecutive hypo- and hyperthyroidism during fetal life. First, hypothyroidism was due to transplacental passage of antithyroid drugs. After the mother's th... | Recovered | ReactionOutcome | CC BY-NC-ND | 33936679 | 19,374,778 | 2021-04 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Contraindicated product administered'. | Effects of concomitant combination of SGLT-2 inhibitor and GLP-1 receptor agonist on renal outcomes in T2D with eGFR below 30 and macroalbuminuria: A case series.
Renal protection is likely to be a class effect of SGLT-2 inhibitors and GLP-1RA. When used simultaneously, there may be a synergistic effect. Both agents ar... | ATORVASTATIN, DAPAGLIFLOZIN, DULAGLUTIDE, ERTUGLIFLOZIN PIDOLATE, INSULIN GLARGINE, INSULIN LISPRO, LOSARTAN POTASSIUM | DrugsGivenReaction | CC BY | 33936685 | 19,358,213 | 2021-04 |
What is the weight of the patient? | Effects of concomitant combination of SGLT-2 inhibitor and GLP-1 receptor agonist on renal outcomes in T2D with eGFR below 30 and macroalbuminuria: A case series.
Renal protection is likely to be a class effect of SGLT-2 inhibitors and GLP-1RA. When used simultaneously, there may be a synergistic effect. Both agents ar... | 87.1 kg. | Weight | CC BY | 33936685 | 19,358,213 | 2021-04 |
What was the dosage of drug 'ATORVASTATIN'? | Effects of concomitant combination of SGLT-2 inhibitor and GLP-1 receptor agonist on renal outcomes in T2D with eGFR below 30 and macroalbuminuria: A case series.
Renal protection is likely to be a class effect of SGLT-2 inhibitors and GLP-1RA. When used simultaneously, there may be a synergistic effect. Both agents ar... | 20 MILLIGRAM | DrugDosageText | CC BY | 33936685 | 19,358,213 | 2021-04 |
What was the dosage of drug 'DAPAGLIFLOZIN'? | Effects of concomitant combination of SGLT-2 inhibitor and GLP-1 receptor agonist on renal outcomes in T2D with eGFR below 30 and macroalbuminuria: A case series.
Renal protection is likely to be a class effect of SGLT-2 inhibitors and GLP-1RA. When used simultaneously, there may be a synergistic effect. Both agents ar... | 5 MILLIGRAM | DrugDosageText | CC BY | 33936685 | 19,358,213 | 2021-04 |
What was the dosage of drug 'ERTUGLIFLOZIN PIDOLATE'? | Effects of concomitant combination of SGLT-2 inhibitor and GLP-1 receptor agonist on renal outcomes in T2D with eGFR below 30 and macroalbuminuria: A case series.
Renal protection is likely to be a class effect of SGLT-2 inhibitors and GLP-1RA. When used simultaneously, there may be a synergistic effect. Both agents ar... | 15 MILLIGRAM DAILY | DrugDosageText | CC BY | 33936685 | 19,358,213 | 2021-04 |
What was the dosage of drug 'INSULIN LISPRO'? | Effects of concomitant combination of SGLT-2 inhibitor and GLP-1 receptor agonist on renal outcomes in T2D with eGFR below 30 and macroalbuminuria: A case series.
Renal protection is likely to be a class effect of SGLT-2 inhibitors and GLP-1RA. When used simultaneously, there may be a synergistic effect. Both agents ar... | 4?8 UNITS WITH EACH MEAL,STRENGTH REPORTED AS U?100 | DrugDosageText | CC BY | 33936685 | 19,358,213 | 2021-04 |
What was the dosage of drug 'LOSARTAN POTASSIUM'? | Effects of concomitant combination of SGLT-2 inhibitor and GLP-1 receptor agonist on renal outcomes in T2D with eGFR below 30 and macroalbuminuria: A case series.
Renal protection is likely to be a class effect of SGLT-2 inhibitors and GLP-1RA. When used simultaneously, there may be a synergistic effect. Both agents ar... | 100 MILLIGRAM | DrugDosageText | CC BY | 33936685 | 19,358,213 | 2021-04 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Off label use'. | Management of refractory Mycobacterium abscessus sternal infection following reoperative cardiac surgery.
Mycobacterium abscessus surgical site infections are rare, but notoriously difficult to treat. Eradication requires aggressive surgical resection, removal of foreign material, prolonged antibiotics, and considerati... | AMIKACIN, AZITHROMYCIN ANHYDROUS, CILASTATIN SODIUM\IMIPENEM, CLOFAZIMINE, TIGECYCLINE | DrugsGivenReaction | CC BY | 33936688 | 19,299,358 | 2021-04 |
What was the administration route of drug 'AMIKACIN'? | Management of refractory Mycobacterium abscessus sternal infection following reoperative cardiac surgery.
Mycobacterium abscessus surgical site infections are rare, but notoriously difficult to treat. Eradication requires aggressive surgical resection, removal of foreign material, prolonged antibiotics, and considerati... | Intravenous (not otherwise specified) | DrugAdministrationRoute | CC BY | 33936688 | 19,299,358 | 2021-04 |
What was the administration route of drug 'AZITHROMYCIN ANHYDROUS'? | Management of refractory Mycobacterium abscessus sternal infection following reoperative cardiac surgery.
Mycobacterium abscessus surgical site infections are rare, but notoriously difficult to treat. Eradication requires aggressive surgical resection, removal of foreign material, prolonged antibiotics, and considerati... | Oral | DrugAdministrationRoute | CC BY | 33936688 | 19,299,358 | 2021-04 |
What was the administration route of drug 'CILASTATIN SODIUM\IMIPENEM'? | Management of refractory Mycobacterium abscessus sternal infection following reoperative cardiac surgery.
Mycobacterium abscessus surgical site infections are rare, but notoriously difficult to treat. Eradication requires aggressive surgical resection, removal of foreign material, prolonged antibiotics, and considerati... | Intravenous (not otherwise specified) | DrugAdministrationRoute | CC BY | 33936688 | 19,299,358 | 2021-04 |
What was the administration route of drug 'CLOFAZIMINE'? | Management of refractory Mycobacterium abscessus sternal infection following reoperative cardiac surgery.
Mycobacterium abscessus surgical site infections are rare, but notoriously difficult to treat. Eradication requires aggressive surgical resection, removal of foreign material, prolonged antibiotics, and considerati... | Intravenous (not otherwise specified) | DrugAdministrationRoute | CC BY | 33936688 | 19,299,358 | 2021-04 |
What was the administration route of drug 'TIGECYCLINE'? | Management of refractory Mycobacterium abscessus sternal infection following reoperative cardiac surgery.
Mycobacterium abscessus surgical site infections are rare, but notoriously difficult to treat. Eradication requires aggressive surgical resection, removal of foreign material, prolonged antibiotics, and considerati... | Intravenous (not otherwise specified) | DrugAdministrationRoute | CC BY | 33936688 | 19,299,358 | 2021-04 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Drug hypersensitivity'. | AGENT ORANGE-INDUCED Anaplastic Large-Cell Lymphoma (ALCL) with Cutaneous Involvement.
Anaplastic large-cell lymphoma (ALCL) is a CD30 + lymphoproliferative disorder that may manifest with skin involvement.1 We present a rare case of Agent Orange-induced ALCL with cutaneous involvement of the hand, surgical excision, a... | SIMVASTATIN | DrugsGivenReaction | CC BY | 33936698 | 19,455,948 | 2021-04 |
What was the administration route of drug 'SIMVASTATIN'? | AGENT ORANGE-INDUCED Anaplastic Large-Cell Lymphoma (ALCL) with Cutaneous Involvement.
Anaplastic large-cell lymphoma (ALCL) is a CD30 + lymphoproliferative disorder that may manifest with skin involvement.1 We present a rare case of Agent Orange-induced ALCL with cutaneous involvement of the hand, surgical excision, a... | Oral | DrugAdministrationRoute | CC BY | 33936698 | 19,455,948 | 2021-04 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Chronic kidney disease'. | Rectal ulcer in a hemodialysis patient receiving Kayexalate®.
Kayexalate can cause severe unrecognized GI lesions. Diagnosis of kayexalate crystals in GI biopsy samples is important. Pathologists and clinicians should work hand in hand. New drugs should be available to all patients to treat hyperkalemia.
1 INTRODUCTION... | IBUPROFEN | DrugsGivenReaction | CC BY | 33936700 | 19,332,177 | 2021-04 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Drug abuse'. | Rectal ulcer in a hemodialysis patient receiving Kayexalate®.
Kayexalate can cause severe unrecognized GI lesions. Diagnosis of kayexalate crystals in GI biopsy samples is important. Pathologists and clinicians should work hand in hand. New drugs should be available to all patients to treat hyperkalemia.
1 INTRODUCTION... | IBUPROFEN | DrugsGivenReaction | CC BY | 33936700 | 19,332,177 | 2021-04 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Duodenal ulcer haemorrhage'. | Rectal ulcer in a hemodialysis patient receiving Kayexalate®.
Kayexalate can cause severe unrecognized GI lesions. Diagnosis of kayexalate crystals in GI biopsy samples is important. Pathologists and clinicians should work hand in hand. New drugs should be available to all patients to treat hyperkalemia.
1 INTRODUCTION... | IBUPROFEN | DrugsGivenReaction | CC BY | 33936700 | 19,332,177 | 2021-04 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Gastric ulcer'. | Rectal ulcer in a hemodialysis patient receiving Kayexalate®.
Kayexalate can cause severe unrecognized GI lesions. Diagnosis of kayexalate crystals in GI biopsy samples is important. Pathologists and clinicians should work hand in hand. New drugs should be available to all patients to treat hyperkalemia.
1 INTRODUCTION... | IBUPROFEN | DrugsGivenReaction | CC BY | 33936700 | 19,332,177 | 2021-04 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Hyperkalaemia'. | Rectal ulcer in a hemodialysis patient receiving Kayexalate®.
Kayexalate can cause severe unrecognized GI lesions. Diagnosis of kayexalate crystals in GI biopsy samples is important. Pathologists and clinicians should work hand in hand. New drugs should be available to all patients to treat hyperkalemia.
1 INTRODUCTION... | IBUPROFEN | DrugsGivenReaction | CC BY | 33936700 | 19,332,177 | 2021-04 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Upper gastrointestinal haemorrhage'. | Rectal ulcer in a hemodialysis patient receiving Kayexalate®.
Kayexalate can cause severe unrecognized GI lesions. Diagnosis of kayexalate crystals in GI biopsy samples is important. Pathologists and clinicians should work hand in hand. New drugs should be available to all patients to treat hyperkalemia.
1 INTRODUCTION... | IBUPROFEN | DrugsGivenReaction | CC BY | 33936700 | 19,332,177 | 2021-04 |
What was the outcome of reaction 'Drug abuse'? | Rectal ulcer in a hemodialysis patient receiving Kayexalate®.
Kayexalate can cause severe unrecognized GI lesions. Diagnosis of kayexalate crystals in GI biopsy samples is important. Pathologists and clinicians should work hand in hand. New drugs should be available to all patients to treat hyperkalemia.
1 INTRODUCTION... | Recovered | ReactionOutcome | CC BY | 33936700 | 19,332,177 | 2021-04 |
What was the outcome of reaction 'Duodenal ulcer haemorrhage'? | Rectal ulcer in a hemodialysis patient receiving Kayexalate®.
Kayexalate can cause severe unrecognized GI lesions. Diagnosis of kayexalate crystals in GI biopsy samples is important. Pathologists and clinicians should work hand in hand. New drugs should be available to all patients to treat hyperkalemia.
1 INTRODUCTION... | Recovered | ReactionOutcome | CC BY | 33936700 | 19,332,177 | 2021-04 |
What was the outcome of reaction 'Gastric ulcer'? | Rectal ulcer in a hemodialysis patient receiving Kayexalate®.
Kayexalate can cause severe unrecognized GI lesions. Diagnosis of kayexalate crystals in GI biopsy samples is important. Pathologists and clinicians should work hand in hand. New drugs should be available to all patients to treat hyperkalemia.
1 INTRODUCTION... | Recovered | ReactionOutcome | CC BY | 33936700 | 19,332,177 | 2021-04 |
What was the outcome of reaction 'Upper gastrointestinal haemorrhage'? | Rectal ulcer in a hemodialysis patient receiving Kayexalate®.
Kayexalate can cause severe unrecognized GI lesions. Diagnosis of kayexalate crystals in GI biopsy samples is important. Pathologists and clinicians should work hand in hand. New drugs should be available to all patients to treat hyperkalemia.
1 INTRODUCTION... | Recovered | ReactionOutcome | CC BY | 33936700 | 19,332,177 | 2021-04 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'General physical health deterioration'. | Neuroleptic malignant syndrome in a patient with moderate intellectual disability treated with olanzapine: A case report.
This case demonstrates the challenges encountered in a case of Neuroleptic Malignant Syndrome in a young woman with moderate Intellectual Disability.
1 INTRODUCTION
We report the case of a 31‐year‐... | DOXYCYCLINE, LORAZEPAM, MIRTAZAPINE, OLANZAPINE, QUETIAPINE, SERTRALINE HYDROCHLORIDE | DrugsGivenReaction | CC BY-NC-ND | 33936704 | 19,108,220 | 2021-04 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Mobility decreased'. | Neuroleptic malignant syndrome in a patient with moderate intellectual disability treated with olanzapine: A case report.
This case demonstrates the challenges encountered in a case of Neuroleptic Malignant Syndrome in a young woman with moderate Intellectual Disability.
1 INTRODUCTION
We report the case of a 31‐year‐... | DOXYCYCLINE, LORAZEPAM, MIRTAZAPINE, OLANZAPINE, QUETIAPINE, SERTRALINE HYDROCHLORIDE | DrugsGivenReaction | CC BY-NC-ND | 33936704 | 19,145,011 | 2021-04 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Neuroleptic malignant syndrome'. | Neuroleptic malignant syndrome in a patient with moderate intellectual disability treated with olanzapine: A case report.
This case demonstrates the challenges encountered in a case of Neuroleptic Malignant Syndrome in a young woman with moderate Intellectual Disability.
1 INTRODUCTION
We report the case of a 31‐year‐... | DOXYCYCLINE, LORAZEPAM, MIRTAZAPINE, OLANZAPINE, QUETIAPINE, SERTRALINE HYDROCHLORIDE | DrugsGivenReaction | CC BY-NC-ND | 33936704 | 19,108,220 | 2021-04 |
What was the outcome of reaction 'General physical health deterioration'? | Neuroleptic malignant syndrome in a patient with moderate intellectual disability treated with olanzapine: A case report.
This case demonstrates the challenges encountered in a case of Neuroleptic Malignant Syndrome in a young woman with moderate Intellectual Disability.
1 INTRODUCTION
We report the case of a 31‐year‐... | Recovering | ReactionOutcome | CC BY-NC-ND | 33936704 | 19,108,220 | 2021-04 |
What was the outcome of reaction 'Mobility decreased'? | Neuroleptic malignant syndrome in a patient with moderate intellectual disability treated with olanzapine: A case report.
This case demonstrates the challenges encountered in a case of Neuroleptic Malignant Syndrome in a young woman with moderate Intellectual Disability.
1 INTRODUCTION
We report the case of a 31‐year‐... | Recovering | ReactionOutcome | CC BY-NC-ND | 33936704 | 19,145,011 | 2021-04 |
What was the outcome of reaction 'Neuroleptic malignant syndrome'? | Neuroleptic malignant syndrome in a patient with moderate intellectual disability treated with olanzapine: A case report.
This case demonstrates the challenges encountered in a case of Neuroleptic Malignant Syndrome in a young woman with moderate Intellectual Disability.
1 INTRODUCTION
We report the case of a 31‐year‐... | Recovering | ReactionOutcome | CC BY-NC-ND | 33936704 | 19,108,220 | 2021-04 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Product use in unapproved indication'. | Fatal invasive pulmonary aspergillosis in an immunocompetent patient with COVID-19 due to Aspergillus terreus: A case study.
Case reports of CAPA emerged. In most of the reports, the predominant species is Aspergillus fumigatus. Uncommon species are less reported. Due to poor clinical outcome with Aspergillus terreus, ... | DEXAMETHASONE, INTERFERON BETA-1A, OXYGEN | DrugsGivenReaction | CC BY-NC-ND | 33936706 | 19,352,215 | 2021-04 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Respiratory failure'. | Fatal invasive pulmonary aspergillosis in an immunocompetent patient with COVID-19 due to Aspergillus terreus: A case study.
Case reports of CAPA emerged. In most of the reports, the predominant species is Aspergillus fumigatus. Uncommon species are less reported. Due to poor clinical outcome with Aspergillus terreus, ... | DEXAMETHASONE, INTERFERON BETA-1A | DrugsGivenReaction | CC BY-NC-ND | 33936706 | 19,448,859 | 2021-04 |
What was the administration route of drug 'DEXAMETHASONE'? | Fatal invasive pulmonary aspergillosis in an immunocompetent patient with COVID-19 due to Aspergillus terreus: A case study.
Case reports of CAPA emerged. In most of the reports, the predominant species is Aspergillus fumigatus. Uncommon species are less reported. Due to poor clinical outcome with Aspergillus terreus, ... | Intravenous (not otherwise specified) | DrugAdministrationRoute | CC BY-NC-ND | 33936706 | 19,448,859 | 2021-04 |
What was the administration route of drug 'INTERFERON BETA-1A'? | Fatal invasive pulmonary aspergillosis in an immunocompetent patient with COVID-19 due to Aspergillus terreus: A case study.
Case reports of CAPA emerged. In most of the reports, the predominant species is Aspergillus fumigatus. Uncommon species are less reported. Due to poor clinical outcome with Aspergillus terreus, ... | Subcutaneous | DrugAdministrationRoute | CC BY-NC-ND | 33936706 | 19,448,859 | 2021-04 |
What was the dosage of drug 'INTERFERON BETA-1A'? | Fatal invasive pulmonary aspergillosis in an immunocompetent patient with COVID-19 due to Aspergillus terreus: A case study.
Case reports of CAPA emerged. In most of the reports, the predominant species is Aspergillus fumigatus. Uncommon species are less reported. Due to poor clinical outcome with Aspergillus terreus, ... | ONCE IN ALTERNATE DAY FOR FIVE DOSES, STOPPED ON DAY 9 | DrugDosageText | CC BY-NC-ND | 33936706 | 19,352,215 | 2021-04 |
What was the dosage of drug 'OXYGEN'? | Fatal invasive pulmonary aspergillosis in an immunocompetent patient with COVID-19 due to Aspergillus terreus: A case study.
Case reports of CAPA emerged. In most of the reports, the predominant species is Aspergillus fumigatus. Uncommon species are less reported. Due to poor clinical outcome with Aspergillus terreus, ... | WITH THE NASAL CANNULA AT 4?5 LITERS PER MINUTE | DrugDosageText | CC BY-NC-ND | 33936706 | 19,352,215 | 2021-04 |
What was the outcome of reaction 'Aspergillus infection'? | Fatal invasive pulmonary aspergillosis in an immunocompetent patient with COVID-19 due to Aspergillus terreus: A case study.
Case reports of CAPA emerged. In most of the reports, the predominant species is Aspergillus fumigatus. Uncommon species are less reported. Due to poor clinical outcome with Aspergillus terreus, ... | Fatal | ReactionOutcome | CC BY-NC-ND | 33936706 | 19,448,859 | 2021-04 |
What was the outcome of reaction 'Bronchopulmonary aspergillosis'? | Fatal invasive pulmonary aspergillosis in an immunocompetent patient with COVID-19 due to Aspergillus terreus: A case study.
Case reports of CAPA emerged. In most of the reports, the predominant species is Aspergillus fumigatus. Uncommon species are less reported. Due to poor clinical outcome with Aspergillus terreus, ... | Fatal | ReactionOutcome | CC BY-NC-ND | 33936706 | 19,448,859 | 2021-04 |
What was the outcome of reaction 'Respiratory failure'? | Fatal invasive pulmonary aspergillosis in an immunocompetent patient with COVID-19 due to Aspergillus terreus: A case study.
Case reports of CAPA emerged. In most of the reports, the predominant species is Aspergillus fumigatus. Uncommon species are less reported. Due to poor clinical outcome with Aspergillus terreus, ... | Fatal | ReactionOutcome | CC BY-NC-ND | 33936706 | 19,448,859 | 2021-04 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Drug interaction'. | Carbon dioxide narcosis in the terminal stage of hemodialysis therapy: A case report with the possible pathophysiologies and the treatment methods.
The cause and treatment of carbon dioxide narcosis in the terminal stage of hemodialysis have not been fully discussed. As we have experienced the case of complete recovery... | AROTINOLOL, AZILSARTAN KAMEDOXOMIL, CALCIUM CHLORIDE\DEXTROSE MONOHYDRATE\MAGNESIUM CHLORIDE\POTASSIUM CHLORIDE\SODIUM BICARBONATE\SODIU, CLOPIDOGREL BISULFATE, FEXOFENADINE HYDROCHLORIDE, LANSOPRAZOLE, PREGABALIN, SODIUM FERROUS CITRATE | DrugsGivenReaction | CC BY | 33936707 | 19,973,415 | 2021-04 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Dyspnoea'. | Carbon dioxide narcosis in the terminal stage of hemodialysis therapy: A case report with the possible pathophysiologies and the treatment methods.
The cause and treatment of carbon dioxide narcosis in the terminal stage of hemodialysis have not been fully discussed. As we have experienced the case of complete recovery... | AROTINOLOL, AZILSARTAN KAMEDOXOMIL, CALCIUM CHLORIDE\DEXTROSE MONOHYDRATE\MAGNESIUM CHLORIDE\POTASSIUM CHLORIDE\SODIUM BICARBONATE\SODIU, CLOPIDOGREL BISULFATE, FEXOFENADINE HYDROCHLORIDE, LANSOPRAZOLE, PREGABALIN, SODIUM FERROUS CITRATE | DrugsGivenReaction | CC BY | 33936707 | 19,973,415 | 2021-04 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Hypozincaemia'. | Carbon dioxide narcosis in the terminal stage of hemodialysis therapy: A case report with the possible pathophysiologies and the treatment methods.
The cause and treatment of carbon dioxide narcosis in the terminal stage of hemodialysis have not been fully discussed. As we have experienced the case of complete recovery... | AROTINOLOL, AZILSARTAN KAMEDOXOMIL, CALCIUM CHLORIDE\DEXTROSE MONOHYDRATE\MAGNESIUM CHLORIDE\POTASSIUM CHLORIDE\SODIUM BICARBONATE\SODIU, CLOPIDOGREL BISULFATE, FEXOFENADINE HYDROCHLORIDE, LANSOPRAZOLE, PREGABALIN, SODIUM FERROUS CITRATE | DrugsGivenReaction | CC BY | 33936707 | 19,973,415 | 2021-04 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Respiratory muscle weakness'. | Carbon dioxide narcosis in the terminal stage of hemodialysis therapy: A case report with the possible pathophysiologies and the treatment methods.
The cause and treatment of carbon dioxide narcosis in the terminal stage of hemodialysis have not been fully discussed. As we have experienced the case of complete recovery... | AROTINOLOL, AZILSARTAN KAMEDOXOMIL, CALCIUM CHLORIDE\DEXTROSE MONOHYDRATE\MAGNESIUM CHLORIDE\POTASSIUM CHLORIDE\SODIUM BICARBONATE\SODIU, CLOPIDOGREL BISULFATE, FEXOFENADINE HYDROCHLORIDE, LANSOPRAZOLE, PREGABALIN, SODIUM FERROUS CITRATE | DrugsGivenReaction | CC BY | 33936707 | 19,973,415 | 2021-04 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Zinc deficiency'. | Carbon dioxide narcosis in the terminal stage of hemodialysis therapy: A case report with the possible pathophysiologies and the treatment methods.
The cause and treatment of carbon dioxide narcosis in the terminal stage of hemodialysis have not been fully discussed. As we have experienced the case of complete recovery... | AROTINOLOL, AZILSARTAN KAMEDOXOMIL, CLOPIDOGREL BISULFATE, FEXOFENADINE HYDROCHLORIDE, LANSOPRAZOLE, PREGABALIN, SODIUM FERROUS CITRATE | DrugsGivenReaction | CC BY | 33936707 | 19,930,421 | 2021-04 |
What was the dosage of drug 'CALCIUM CHLORIDE\DEXTROSE MONOHYDRATE\MAGNESIUM CHLORIDE\POTASSIUM CHLORIDE\SODIUM BICARBONATE\SODIU'? | Carbon dioxide narcosis in the terminal stage of hemodialysis therapy: A case report with the possible pathophysiologies and the treatment methods.
The cause and treatment of carbon dioxide narcosis in the terminal stage of hemodialysis have not been fully discussed. As we have experienced the case of complete recovery... | 35 MEQ/L | DrugDosageText | CC BY | 33936707 | 19,973,415 | 2021-04 |
What was the dosage of drug 'SODIUM FERROUS CITRATE'? | Carbon dioxide narcosis in the terminal stage of hemodialysis therapy: A case report with the possible pathophysiologies and the treatment methods.
The cause and treatment of carbon dioxide narcosis in the terminal stage of hemodialysis have not been fully discussed. As we have experienced the case of complete recovery... | 50 mg (milligrams). | DrugDosage | CC BY | 33936707 | 19,973,415 | 2021-04 |
What was the outcome of reaction 'Dyspnoea'? | Carbon dioxide narcosis in the terminal stage of hemodialysis therapy: A case report with the possible pathophysiologies and the treatment methods.
The cause and treatment of carbon dioxide narcosis in the terminal stage of hemodialysis have not been fully discussed. As we have experienced the case of complete recovery... | Recovering | ReactionOutcome | CC BY | 33936707 | 19,973,415 | 2021-04 |
What was the outcome of reaction 'Hypercapnia'? | Carbon dioxide narcosis in the terminal stage of hemodialysis therapy: A case report with the possible pathophysiologies and the treatment methods.
The cause and treatment of carbon dioxide narcosis in the terminal stage of hemodialysis have not been fully discussed. As we have experienced the case of complete recovery... | Recovering | ReactionOutcome | CC BY | 33936707 | 19,973,415 | 2021-04 |
What was the outcome of reaction 'Hypozincaemia'? | Carbon dioxide narcosis in the terminal stage of hemodialysis therapy: A case report with the possible pathophysiologies and the treatment methods.
The cause and treatment of carbon dioxide narcosis in the terminal stage of hemodialysis have not been fully discussed. As we have experienced the case of complete recovery... | Recovering | ReactionOutcome | CC BY | 33936707 | 19,973,415 | 2021-04 |
What was the outcome of reaction 'Respiratory muscle weakness'? | Carbon dioxide narcosis in the terminal stage of hemodialysis therapy: A case report with the possible pathophysiologies and the treatment methods.
The cause and treatment of carbon dioxide narcosis in the terminal stage of hemodialysis have not been fully discussed. As we have experienced the case of complete recovery... | Recovering | ReactionOutcome | CC BY | 33936707 | 19,973,415 | 2021-04 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Disease recurrence'. | Low-dose aspirin-induced gastric mucosal injury after Fontan surgery in an adolescent.
Low-dose aspirin (LDA)-induced gastric mucosal injury always requires rigorous follow-up while taking LDA, even in adolescents, and after a long time from the start of LDA.
1 INTRODUCTION
It is important to undergo more rigorous fol... | ASPIRIN, DIGOXIN, ECABET SODIUM, ENALAPRIL, ESOMEPRAZOLE MAGNESIUM, SODIUM ALGINATE | DrugsGivenReaction | CC BY-NC-ND | 33936713 | 19,148,711 | 2021-04 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Gastric mucosal lesion'. | Low-dose aspirin-induced gastric mucosal injury after Fontan surgery in an adolescent.
Low-dose aspirin (LDA)-induced gastric mucosal injury always requires rigorous follow-up while taking LDA, even in adolescents, and after a long time from the start of LDA.
1 INTRODUCTION
It is important to undergo more rigorous fol... | ASPIRIN, DIGOXIN, ECABET SODIUM, ENALAPRIL, ESOMEPRAZOLE MAGNESIUM, SODIUM ALGINATE | DrugsGivenReaction | CC BY-NC-ND | 33936713 | 19,148,711 | 2021-04 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Therapeutic product effect incomplete'. | Low-dose aspirin-induced gastric mucosal injury after Fontan surgery in an adolescent.
Low-dose aspirin (LDA)-induced gastric mucosal injury always requires rigorous follow-up while taking LDA, even in adolescents, and after a long time from the start of LDA.
1 INTRODUCTION
It is important to undergo more rigorous fol... | ASPIRIN, DIGOXIN, ECABET SODIUM, ENALAPRIL, ESOMEPRAZOLE MAGNESIUM, SODIUM ALGINATE | DrugsGivenReaction | CC BY-NC-ND | 33936713 | 19,148,711 | 2021-04 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Intentional product use issue'. | Leg ulcer with long-term hydroxyurea use.
Long-term use of hydroxyurea can cause leg ulcers which usually do not heal unless the drug is discontinued. Patients should be counseled regarding alternative lines of treatment like anagrelide and pegylated-interferon.
A 63‐year‐old nondiabetic male with a history of essentia... | HYDROXYUREA | DrugsGivenReaction | CC BY | 33936725 | 19,020,444 | 2021-04 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Skin ulcer'. | Leg ulcer with long-term hydroxyurea use.
Long-term use of hydroxyurea can cause leg ulcers which usually do not heal unless the drug is discontinued. Patients should be counseled regarding alternative lines of treatment like anagrelide and pegylated-interferon.
A 63‐year‐old nondiabetic male with a history of essentia... | HYDROXYUREA | DrugsGivenReaction | CC BY | 33936725 | 19,020,444 | 2021-04 |
What was the outcome of reaction 'Skin ulcer'? | Leg ulcer with long-term hydroxyurea use.
Long-term use of hydroxyurea can cause leg ulcers which usually do not heal unless the drug is discontinued. Patients should be counseled regarding alternative lines of treatment like anagrelide and pegylated-interferon.
A 63‐year‐old nondiabetic male with a history of essentia... | Recovering | ReactionOutcome | CC BY | 33936725 | 19,020,444 | 2021-04 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Fungal infection'. | Disseminated Saprochaete capitata fungal infection in a patient with acute myeloid leukemia.
The case highlights the importance of actively obtaining informative samples at an early stage and of prompt initiation of combination therapy with antifungal drugs.
We report the case of a 66‐year‐old Caucasian woman who prese... | CYTARABINE, IDARUBICIN | DrugsGivenReaction | CC BY-NC-ND | 33936726 | 19,401,878 | 2021-04 |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.